SVRA · XBRL financial data

Savara financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SVRA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	257	—	—	—	—	—
General and administrative	14,264	12,350	10,929	15,668	25,037	42,056
Total operating expenses	49,557	41,477	38,839	60,007	103,196	123,547
Operating income (loss)	(49,300)	(41,477)	(38,839)	(60,007)	(103,196)	(123,547)
Other income (expense)	(315)	(1,537)	689	5,309	7,315	4,710
Income tax expense (benefit)	—	—	—	—	9	0
Net income (loss)	(49,615)	(43,014)	(38,150)	(54,698)	(95,881)	(118,837)
Earnings per share, basic USD per share	—	(0.32)	(0.25)	(0.33)	(0.48)	(0.53)
Earnings per share, diluted USD per share	—	(0.32)	(0.25)	(0.33)	(0.48)	(0.53)
Weighted average shares, basic thousands of shares	—	133,919	152,772	165,205	198,192	222,388
Weighted average shares, diluted thousands of shares	—	133,919	152,772	165,205	198,192	222,388

Fiscal years (SVRA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	22,880	34,012	52,100	26,585	15,128	33,180
Short-term investments	59,308	127,159	73,776	135,734	181,199	202,522
Prepaid and other current assets	2,933	3,829	3,078	3,628	5,808	5,914
Total current assets	85,121	165,000	128,954	165,947	202,135	241,616
Property and equipment, net	156	73	51	270	165	100
Right-of-use asset	200	300	100	400	200	100
Goodwill	0	—	—	—	—	—
Total assets	97,745	176,598	139,777	177,564	212,879	253,436
Accounts payable	2,595	1,443	1,334	3,504	4,545	5,757
Accrued liabilities	5,579	4,884	4,533	7,093	10,179	14,639
Current portion of long-term debt	—	8,333	—	—	0	0
Total current liabilities	8,174	14,660	5,867	10,597	14,724	20,396
Long-term debt	25,104	17,323	26,078	26,348	26,619	29,907
Lease liability, non-current	100	100	50	200	100	—
Total liabilities	33,362	32,100	31,999	37,192	41,430	50,303
Accumulated deficit	(257,507)	(300,521)	(338,671)	(393,369)	(489,250)	(608,087)
Total stockholders' equity	64,383	144,498	107,778	140,372	171,449	203,133
Total liabilities and equity	97,745	176,598	139,777	177,564	212,879	253,436
Common shares outstanding (cover page) thousands of shares	54,236	114,040	114,065	138,148	172,633	204,657

Fiscal years (SVRA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(49,615)	(43,014)	(38,150)	(54,698)	(95,881)	(118,837)
Stock-based compensation	5,107	3,260	2,041	4,178	9,860	14,421
Net cash from operating activities	(39,836)	(40,081)	(34,554)	(51,061)	(89,088)	(101,037)
Purchases of property and equipment	47	57	9	296	25	22
Net cash from investing activities	9,053	(69,456)	52,645	(57,116)	(39,941)	(18,440)
Proceeds from issuing common stock	2,290	—	—	—	—	—
Proceeds from long-term debt	—	—	26,438	—	—	29,598
Repayments of long-term debt	514	—	26,350	—	—	27,229
Net cash from financing activities	3,689	120,806	87	82,780	117,577	137,806
Net change in cash	(26,924)	11,132	18,088	(25,515)	(11,457)	18,052

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	110,768	99,313	(60,841)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39,416	32,355	10,070	1.1B	—	Q1 FY27 10-QJun 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Trevi Therapeutics	54,302	not reported	(17,429)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107,271	11,255	(62,686)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.